logo-loader
RNS
OptiBiotix Health PLC

OptiBiotix Health - Statement: SkinBioTherapeutics Announcement

RNS Number : 2389T
OptiBiotix Health PLC
17 February 2026
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

Statement: SkinBioTherapeutics Announcement

 

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes provides a statement relating to the recent announcements made by SkinBioTherapeutics ("SBTX").

OptiBiotix recognises the uncertainty in the market from recent announcements by SBTX and its impact on the value of the Company's 5.64% holding in SBTX. OptiBiotix confirms it has no current intention to sell its SBTX shares. The Company confirms it has not sold any ProBiotix Health ("PBX") shares and has no current plans to sell PBX shares.

The Company's unaudited cash position as of 31st December 2025 was just over £1 million (2024: £739k) with no current requirement to raise new funds.  The Company's focus is on increasing sales, improving margins, and reducing costs to develop a sustainable business, and launching its second-generation products. Considerable progress has already been made in growing sales, particularly of high margin product lines, with orders for 2026 previously reported of over £800K (announced: 21 January 2026).  The Company has developed profit and loss accounts for each part of its business (OptiBiotix Health USA, OptiBiotix Health India, Ecommerce and B2B) with each business unit tasked with covering its direct costs by the end of 2026. Considerable progress has also been made in January 2026 in managing marketing spend in Ecommerce with its Amazon account now profitable and its China Ecommerce account anticipated to be profitable in forthcoming months.

Stephen O'Hara, CEO of OptiBiotix, commented:

"The board recognises the uncertainty recent announcements by SBTX have had on the value of its holding in SBTX and indirectly in OPTI itself.  The Company believes the fundamentals of its business are strong and reminds investors of material progress in its SweetBiotix products (announced: 24 November 2025) and a recent large order from Meelung of 24mt (announced: 21 January 2026) and record start to 2026. The Board believes it is in the strongest position it has been in with its first-generation products and making strong progress with its second-generation products."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say by subscribing to the new website to get regular updates:  https://optibiotix.com/auth/signup

View the full announcement and submit questions to management via our website: https://optibiotix.com/link/PmpRXr

 

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

 

Stephen O'Hara, Chief Executive


 


Cairn Financial Advisers LLP (NOMAD and Broker)

Tel: 020 7213 0880

Liam Murray / Ludovico Lazzaretti / James Western

 


About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease.  Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions.  These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUNVBRNVUUAAR
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read